洛丽塔

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。    AI摘要      8月18日，3000公斤连江鲜活贻贝首次直供台湾。在榕城海关精准帮扶下，产品通过严格监管顺利出口，标志着闽台渔业深度融合取得新进展。         8月18日，3000公斤鲜活贻贝经福州海关所属榕城海关严格监管合格，从连江养殖基地完成装车封装，销往中国台湾地区。这是连江鲜活贻贝首次直供台湾市场。    连江贻贝个头饱满、肉质鲜美，在国内市场收获良好口碑。但多数养殖户和水产企业因不熟悉两岸贸易规则与通关流程，优质贻贝产品长期无法顺利输台。为此，榕城海关联合连江当地部门靠前服务、精准帮扶，推行“一地一策、一品一策、一企一策”服务模式。工作人员全程指导养殖基地优化养殖流程、完善全链条质量管控体系，协助企业取得出境水生动物养殖场注册资质，严格落实疫病监测、安全风险排查等管控举措，全方位保障出口贻贝品质达标。连江鲜活贻贝首次成功输台，是闽台渔业深度融合的生动实践。

Current article:http://www.chenzhuaigecoupuhongyuntuizei.sbs/vsq/20260826/18482.pptx

Published on:11:11:43